Plasma cytokine profiles at diagnosis in pediatric patients with non-hodgkin lymphoma

Journal of Pediatric Hematology/Oncology

Volumn 34, Issue 4, 2012, Pages 271-275

  Mellgren, Karin ^a,b   Hedegaard, Chris Juul ^c   Schmiegelow, Kjeld ^d,e   Müller, Klaus ^c,e  

^a QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Institute for Inflammation Research   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e University of Copenhagen   (Denmark)

Author keywords

Biological markers; Cytokine profile; Non Hodgkin lymphoma; Pediatric patients

Indexed keywords

CXCL9 CHEMOKINE; EOTAXIN; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ARTICLE; B CELL LYMPHOMA; BLOOD SAMPLING; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; HEALTH STATUS; HUMAN; LARGE CELL LYMPHOMA; LYMPHOBLASTOMA; MALE; NONHODGKIN LYMPHOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SWEDEN;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HUMANS; INFANT; LYMPHOMA, NON-HODGKIN; MALE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RETROSPECTIVE STUDIES;

EID: 84860785219     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182431e02     Document Type: Article

References (31)

1. Verdame E, Martinez-Maza O. Assessment of prediagnosis biomarkers of immune activation and inflammation: insight on the etiology of lymphoma. J Proteome Res. 2011;10:113-119.
2. Manovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436-444.
3. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse largecell lymphomas. Nature. 2001;412:341-346. (Pubitemid 32691848)
4. Epeldegui M, Widney DP, Martinez-Maza O. Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B-cell activation-associated molecular lesions. Curr Opin Oncol. 2006;18:444-448. (Pubitemid 44199839)
5. Purdue MP, Lan Q, Martinez-Maza O, et al. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood. 2009;114:2730-2732.
6. Gu Y, Shore RE, Arslan AA, et al. Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study. Cancer Causes Control. 2010;21:1323-1333.
7. Skibola CF, Bracci PM, Nieters A, et al. Tumor necrosis factor (TNF) and lymphotoxin-a (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol. 2010;171:267-276.
8. Saberi Hosnijeh F, Krop E, Scoccianti C, et al. Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2010;19:1577-1584.
9. Stasi R, Zinzani L, Galieni P, et al. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma. Eur J Haematol. 1995;54:9-17.
10. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7:27-38. (Pubitemid 43025390)
11. De Jong D, Enblad G. Inflammatory cells and immune microenvironment in malignant lymphoma. J Intern Med. 2008;264:528-536.
12. Herreros B, Sanchez-Aguilera A, Piris MA. Lymphoma microenvironment: culprit or innocent? Leukemia., 2008, 22, 49-58.
13. Reiter A, Schrappe M, Yakisan E, et al. NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 3: an intermediate term analysis of the B-NHL/B-ALL. Klin Padiatr. 1994;206:242-252. (In German). (Pubitemid 24248160)
14. Woessmann W, Seidemann K, Mann G, et al. BFM Group. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105:948-958. (Pubitemid 40170860)
15. Má rky I, Björk O, Forestier E, et al. Nordic Society of Pediatric Hematology and Oncology. Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the Nordic Society of Pediatric Hematology and Oncology. J Pediatr Hematol Oncol. 2004;26:555-560. (Pubitemid 39223663)
16. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse Bnon-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHLBFM 90. Blood. 2001;97:3699-3706.
17. Brugières L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27:897-903.
18. Gross TG, Filipovich AH, Conley ME, et al. Cure of X-linked lymphoproliferative disease (XLP) with allogenic hematopoietic stem cell transplantation. Report from the XLP registry. Bone Marrow Transplant. 1996;17:741-744. (Pubitemid 26156307)
19. Bjrnhart B, Svenningsen P, Gudbrandsdottir S, et al. Plasma TNF binding capacity in patients with juvenile idiopathic arthritis. Int Immunopharmacol. 2005;5:67-71.
20. Gross HJ, Hermann F, Drezler HG. Hodgkin's disease: a cytokine producing tumour: a review. Crit Rev Oncol. 1994;5:473-538.
21. Maggio E, van den BA, Diepstra A, et al. cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol. 2002;13(suppl 1):52-56. (Pubitemid 34567402)
22. Bouchard F, Bélanger SD, Biron-Pain K, et al. EGR-1 activation by EGF inhibits MMP-9 expression and lymphoma growth. Blood. 2010;116:759-766.
23. Nakamura T, Mizuno S. Review: the discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B. 2010;86:588-610.
24. Trusolono L, Bertotti A, Comoglio PM. Met signaling: principles and functions in development, organ regeneration and cancer. Nat Rev. 2010;11:834-848.
25. Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer. 2006;119:477-483. (Pubitemid 43955698)
26. Hübinger G, Scheffrahn I, Müller E, et al. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation. Exp Hematol. 1999;27:1796-1805.
27. Horie R, Watanabe M, Ishida T, et al. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NFkappa B activation in anaplastic large cell lymphoma. Cancer Cell. 2004;5:353-364. (Pubitemid 38482071)
28. Seidemann K, ZimmermannM, Book M, et al. Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Münster trial NHL-BFM 95. J Clin Oncol. 2005;23:8414-8421.
29. Rautonen J, Simes MA. Glycosylated and total hemoglobin concentrations as prognostic factors in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1989;6:45-50. (Pubitemid 19081168)
30. Ek T, Mellander L, Abrahamsson J. Interferon g and tumour necrosis factor a in relation to anemia and prognosis in childhood cancer. Acta Paediatr. 2005;94:435-437.
31. Broxmeyer HE, Williams DE, Lu L, et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol. 1986;136:4487-4495. (Pubitemid 16090666)